Menu
GeneBe

CCR10

C-C motif chemokine receptor 10, the group of C-C motif chemokine receptors

Basic information

Region (hg38): 17:42678888-42683917

Previous symbols: [ "GPR2" ]

Links

ENSG00000184451NCBI:2826OMIM:600240HGNC:4474Uniprot:P46092AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CCR10 gene.

  • Inborn genetic diseases (15 variants)
  • not provided (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CCR10 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
1
missense
14
clinvar
1
clinvar
1
clinvar
16
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
0
Total 0 0 14 1 2

Variants in CCR10

This is a list of pathogenic ClinVar variants found in the CCR10 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
17-42679593-G-A not specified Uncertain significance (May 27, 2022)2292152
17-42679645-C-T not specified Uncertain significance (Oct 17, 2023)3140073
17-42679657-T-C not specified Likely benign (Jan 04, 2022)2269723
17-42679665-C-T not specified Uncertain significance (Mar 02, 2023)2465019
17-42679710-G-C not specified Uncertain significance (Sep 27, 2021)2252292
17-42679791-G-T not specified Uncertain significance (Nov 21, 2022)2382812
17-42679843-G-T not specified Uncertain significance (Aug 02, 2022)2401913
17-42680152-T-C not specified Uncertain significance (Nov 15, 2021)2389316
17-42680177-G-C Benign (Dec 31, 2019)785571
17-42680197-C-A not specified Uncertain significance (Feb 23, 2023)2488504
17-42680215-C-T not specified Uncertain significance (Nov 30, 2022)2330218
17-42680224-C-A not specified Uncertain significance (Nov 17, 2022)2326523
17-42680307-G-A not specified Uncertain significance (Feb 28, 2024)3140070
17-42680409-G-A not specified Uncertain significance (Sep 20, 2023)3140069
17-42680466-T-C not specified Uncertain significance (Sep 22, 2022)2312730
17-42680491-C-T not specified Uncertain significance (Jul 11, 2023)2591474
17-42680497-G-C not specified Uncertain significance (Nov 10, 2022)2325896
17-42680559-G-C not specified Uncertain significance (May 17, 2023)2547418
17-42680565-G-A not specified Uncertain significance (Dec 08, 2023)3140071
17-42680574-G-A not specified Uncertain significance (Oct 25, 2022)2378537
17-42681816-G-A Benign (Feb 08, 2018)712744
17-42682613-G-C Benign (Sep 04, 2019)1286631
17-42682829-CATGATGCATCTCCGGCTCTTCTGCATCCTGCTCGCCGCGGTCTCAGGAGCCGAGGGCTGGGGCTACTGTGAGTGTTGGGCTTGGAGGCAGGTGGGGTTGGGCCCAGGAGTCCAGAGCCTGCAGGGCGGCCCCGAACCGCATTGCGGCTGGGTGGTCGCGGGTCCTTCCCGGCCGGCGCGCGCCCGCTGGCTCTCATCTTTTCCTGCCTCTCCCCCGCGCTCCGCATTGCAGCTCTGAGGCTGCCGCGCGCGCCCGGGGCTGGGGCTGGGCTCTGGGAAGAGGATGAAGTCAGCGGGCAGGGATTTGGGGTTGGGATCCAAGCAGGAGCTGGTGCCTGGGTTTGAGGCTAGGGCTGGGGGATAAGTGTATACTGGTGACCGATACTAGGATTAAGGTTTTGCCAGGGCTTAAGGCTGGACTTTGGAGCTGGCCAAGGGGTGGGGTTTGTGGCTAGGGCTGGGGTTTGTGGCTGGGGCTGGGTTTTGTGGCAGGGATCCAAGCAGGAGCTGGTGCCCCTGACTGATGCTAAGGCTGGACATGGAGCTGGTGATGGTGCTAGCACTGGCTGAGGTTGGGTGCAAGGCCTGTATTTGGGGATGGTGCAGGTTTTGGGGGCCGAGTTGGATTGAGGCTAGGGTTGGAGCTGGATTGGTGTCTTGGGTTGACTTAGGTTGTGGAAGATGCTGAGGTTTAGGATTGAGTTTGGGAAAGTACTAAACCAGGGCAGGTATTGGGCTAGCTAGGGAGGGTCTGGCCTTGGGCCTATAGGTGTAGCCTAGGGGTTTGCCTAGAAGGAGAAGGTAGCCTCCTCTGAGCATGCAGCTGTTGCTGCAGCCAGGATTGAATAGATGGCTTTAAGGTAGGGCTGGGTGTGCCTCTGGGGGCGGGGGTTGGGGGCACGGAAGGGGAAGCTTCGGTCGCTAAGTGGGCCGGCCTTTGGAAGGGTCTGGGAGGGGCCAGCGCTGACTAACAGTCGGTTTCCCTACCCTAGACGGCTGCGACGAGGAGCTGGTGGGTCCCCTGTATGCACGCTCCCTGGGCGCCTCCTCCTACTACAGTCTCCTTACTGCGCCGAGATTCGCCAGGCTGCACGGTGAGCTCCGCGGAACATCAGCTGCCAACTGGCAGCGCACCGCGGAAGGGTGGGGGCCTCCGGAGGACTTCGGGGAGAGGGATAGCCGGTTAAAGCTCCTGTCCTTTCTATAGGCATAAGCGGGTGGTCACCACGGATTGGGGATCCGAATCCCTGGCTCCAGATAGACTTAATGAAGAAGCACCGGATCCGGGCCGTGGCCACACAGGGCTCCTTTAATTCTTGGGACTGGGTCACACGTTACATGCTACTCTACGGCGACCGAGTGGACAGCTGGACACCGTTCTACCAGCGAGGGCACAACTCGGTACTCTGGGCGCCAAGGCGGTAACACTTGGGGAGCTTCCTCTGCTCCAGGCTCTGGGCCGGGCACCAGCCTCTGGGAAAATGGAGGGGGTGGTGGTGAGGGCTCGGACAAGGAGCAGTGACTCCACTCCAGGGACTCTGTCCAGAGGGACTGTCAGCTTAGGACGTGCGCGAAACACTCGGTTCACAGGGTTTAACACACTTTAGGGTAAAACCTGGGAGAGCTTCCTAAGGAGGTGACATTTGATTTCAGGTCTGAGGAAATAATAGGATTGTGGGACAGGGCACTTTATGGAAACTGTGCGGGCAAAGCCGCCAAGCAGGGAAGACCAAGGAGTGTTTACTTTCCAGAAGTCGAGATTGGCTGGGTGTGAAAGTTGTGGGCTGGGAGGCTATGGAGAAAGAAGCAGAGGGGGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATCACGAGGTCAGGAGTTCATGACCAGCCTGGCCAACATGGTGAAACCCCGTCTCTATGAAAAATACAAAAAAATCAGCCGGGCGTAGTGGCGGGCGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGAAGAGAATTGTTTGAACCCGGGAGGCAGAGGTTGCGGTGAGCCGAGATCGTACCACCGCACTCCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAAATAAAATAAAAAAAAGAAGCAGAGGGCAGGACGTGGTTACTACTCTCCTCCACCCCCGCAGACCTTCTTTGGTAACGTGAACGAGTCGGCGGTGGTGCGCCATGACCTGCACTTCCACTTCACTGCGCGCTACATCCGCATCGTGCCCCTGGCCTGGAACCCACGCGGCAAGATCGGCCTGAGGCTCGGCCTCTATGGCTGCCCATACAGTAAGTGTGCAGAGAGCGCGGAGGGGGCCTGGGAGACAGCCTCCCCAGTTCCCGGCCCACCTACGGTCCTTTGCGCAGAGGCCGACATACTCTATTTCGACGGCGACGATGCCATCTCCTACCGCTTCCCGCGAGGGGTCAGCCGAAGCCTGTGGGACGTGTTCGCCTTCAGCTTCAAGACCGAGGAGAAGGACGGTCTTCTGCTGCACGCCGAGGGCGCCCAGGGCGACTACGTGACGCTCGAGCTGGAGGGGGCACACCTGCTGCTGCACATGAGCCTGGGTGAGCTCGGCGACCATGTGCGATGCGGAGCCAACCCCTGAAGCTCTCTCACCGCCCTCCTCGTGGCACCTCCTCCGCGCATCCGCGCTCAGCCTGGTCTTCCACTTCTCTAAGGCCTGGACCAAACTGCCCCTTTCTTGTAGCATTTGGTGCTAGCAAAACACTGGAGTTGAGTGAGAACTGGATTCCAGTCTCAGCTCTACCACTACACAGAGATGTGACCTCGGATGGGGCACTTCCGAGCCTCAGTTCCCTCCTTGTAAACACACACACACAGACGCACACACATTGTATCTCATTAGCTTTTCATAACACCCGCACATGAAATAGAAGCAGCTCATGTGTTCCCAGTTTTACAGACAGGAAGCCAGGCTAAATGGCTTACCCTGTCACACACTCGCCAATGGCTGTTGATCTATTCGCCCACTCTCCCTGATTGCCCTGGGCTTTGTTACACGCTGCTGCTCTGCCTAGGAGCTTGGACTCCATGGAGTTCTCCTGGCTTGAGGTTTCACTCTGTCCTGCCCCACCCTCAGGCAGCAGCCCTATCCAGCCAAGACCAGGTCACACCACCGTGAGCGCAGGCGGAGTCCTCAATGACCAGCACTGGCACTATGTGCGGGTGGACCGATTTGGCCGCGATGTAAATTTCACCCTGGACGGCTATGTGCAGCGCTTTATTCTCAATGGAGACTTCGAGAGGCTGAACCTGGACACTGAGGTGAGAGACTAGGGAGGTGCTATTTCGTGGTAGGGTAGATGCTGGATGAGTGAGTGCAGGTCGGTCTCTCCCTTTCTCTTTTCCTCTGTCTCTCAGAGGAAAGACCTGGCATTCAGGCTGTGGGTGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGAGGATTGCTTGAGGCCAGGTGTTCAAGACTCACCTGGGCAACATAGTGACATCCTACCTCTATTTAAAAAAATTTTTTTTTTCAAAGACCTCGCATTCCAATTCCTGAATATCCTAGCAGCCCTTGGCAAACTTGCCACTCACCAGAAAAAGGCCTGTTTTTTTTTTTTTTTTTTTTTTTTGTGGGTGTTGTTGCTGTTAGCATGCAGACTCCCAGGCACTATTTCAGAACTAATGAGATGGGGTTTGGAAATTCAGATTTTGGGGACTAGGCAAGGTAGGAAAATTGTTCCCTTGGATCCTCCCACAACTTTGTGGAGTTGTTAAAGACCCTGACCCCATCTGCAGATAAGAATCCCAGGCAGGCTAATTGACTTGCCCAAGGGCGTGCAGCCGATTTGTGTTGGAGTCAGAGCTTGAACTCAAGCCTTGAAAGGCCTAGCGAGCTTTAGTACCGACACTGGGGAAATGTGTGTTTTAAGTCTTTTACAAAACCCCATCTGGCATTTGGGAAAGCATACGGCGGGGACGCGCGAGAAAGGCAGGCGCCCTCCTGTGCCCAAGAGGCCTCATTCCCCACGCCTCCCGCAGATGTTCATCGGAGGTCTGGTGGGCGCCGCGCGGAAGAACCTGGCCTATCGGCATAACTTCCGCGGCTGCATAGAAAACGTAATCTTCAACCGCGTCAACATCGCAGACCTGGCCGTGCGGCGCCATTCCCGGATCACCTTCGAGGCCAGTGGGCAGGGGGGTCTGGGAGGACAGGATATCAAAGCGTCGTGGAAAGCAAAGAGGTGGAGCGGGAAGAGATATTGAACATCAGATAAAAGCGGAGAATCCCTCTGTCCCCAGCCAGATGCTCAAGTTGGGAGGGGAGCGGGTCTCACCTGAGGTGCATGAGCCACGCAGGCCCCTAGTTAAGAAGCAGTGGTCGGGTCCAATCACCTTCTTAGTTCATAGATGAAGAAAGTAAGGCGCAGACACAGGGAGTGGCTTGTCCAGGGGTCGTGCAGCTGCACGGTGGCTGAGTAGGGACTTGAACCGATGGCTTCTCTGATATGCCCCCCTCAACCCTCTCCGACTCTGGAGCTCTGTTGGGAAGCTGGCAGGAGCCAGGTCTGTGGTCCAAAATTGCCTCTCGATACTGGAAGGAGAGAAGCGGTCGAATCGCAGACGGTGGAGATCAGCGAGAGCAAGCGAGCAGAGTTCCGAGGGCCGACTGGGTTGGGGCCCCCTCCACAGATGGACGAGCTTGGAGGGGAAGAGGTCACGTCATGGTTGGAGATCTCACCCCCGCCAACACCGAAGGAGGGCGGTGACCAGGGTCTTAGACCGGTGTGAAAACTGAATTCCCAGCTGAGGCAGAGGCGGCTCACGGGTGTTGATGCGTCTTCACTTTTGCCCCTAGGGTAAGGTGGCTTTTCGTTGCCTGGACCCGGTACCGCACCCTATCAACTTCGGAGGCCCTCACAACTTCGTTCAAGTGCCCGGTTTCCCACGCCGTGGCCGCCTGGCAGTCTCATTTCGCTTCCGCACCTGGGACCTCACCGGGCTTCTCCTTTTCTCCCGTCTGGGGGACGGGCTGGGCCACGTGGAGCTGACGCTCAGCGAAGGGCAGGTCAACGTGTCCATCGCGCAGAGCGGCCGAAAGAAGCTTCAGTTCGCTGCTGGTGAGGGCGTTTCGGGGGAGGCACAAGAAGAGAAGAGAAGTGTAGAGGATCCCAGGAAAGTTGTAGGCCTGGACTGAGGCCTTTACATTCTGGAGAGGGGAGAGGAGTGAAGGGGGCAGGGCAGGAGGCCCCAGGGTACTGGGAAAAGGTGGGAGTGGCTAGAGGCAGTGAGGAGGCGAATCTGAGGGACTAAGTATTCTTGGAGAAGGGGGAAGCCTGGGAGTCCTGGTATTCTCCAGTTCCAGAAGGCCCCTGGAGATTTGGTTACTCGTTTATAACTGTGCAGACTCTGTGGCAGTTGCTGGGTCATGGATAATGAAGAGACATTCAGAGAGGTCTCCACTGGGTGTGAGAAGTGTAATCACGGGGGCACACAGGCTGCTACTGGGACACAGTGGGGCTGCTGCTTCCCCACTCAGAACATTCTTCTACCCTAGTTGCTGCTTCCCTCCACCCACACCATCATCCATTCTTGTCCAGGGTACCGACTGAATGACGGCTTTTGGCACGAGGTGAATTTTGTGGCACAGGAAAACCATGCAGTTATCAGCATTGATGATGTGGAAGGGGCAGAGGTCAGGGTCTCATACCCGTTGCTGATCCGGACAGGGACCTCATATTTCTTTGGGGGTAAGTGGGGGCCAACCTGACCAGACCTCTGTTTCTGGGTGGGAAGGCTCCATCTAAGTCCACCCAGATGGGGCCACATGGAGAATTTTGGAGGGATCAAGCCCTCTTCCCCTCTGGGGCCTCAGGGAGTGGAAGGTCATTGCCATCTACACTTTGGTTGTAGTCCCCTTTCTTCCTTTATGTCTGGCTCCCCCTCAGCATGTCCCTGGGGGAGGGTCTTTGGGGTCTCCCCTGGGGAGGATCTCACAGGGGTGGTTGCTCCAGGTTGTCCCAAGCCAGCCAGTCGATGGGACTGCCACTCCAACCAGACGGCATTCCATGGCTGCATGGAGCTGCTCAAGGTGGATGGTCAACTGGTCAACCTGACTCTGGTGGAGGGCCGGCGGCTTGGATTCTATGCTGAGGTCCTCTTTGATACATGTGGCATCACTGATAGGTACCCAGAAGCCCCTAACAAGAGATGACCCCTCCAAAGCCCTCTTCCCTGGTCTCCCAGTAGGAATGGCCTCTTTCAATAATCTCCCTTCTCCTTGTCTCTGCTCCTTAGTCCCCTGCTTGGGGATGATTCTTCTTTGATCTCTTACCTCCTATTTCTTCCCTTAAGGTGATACATGCTCAGGATGGAAATGACACATTTGCTTTTGGTCCTAGAGGGGTTTTTTGTGCTAGGGGGATGATAGGGGTAGAATAAGGCATGTTTTGATGTTTTCAGGAAGGGGGAATAGTAGTACTTGAGCCCTGAGGACTGCCTAGTGCCCCTGCATCTGCGCTTATACCCGGCTGGCTAGGCGGGGTGTGTCTCACCGGGTTCTGGGGCTTCAAGGAGCTGGGAGTGAAGCTTGCAGGGATCAGACCCCACTCTCCAGCTCCCAGTAAGGCTCCTTCCCTTGGTCCTGACCCCTTCCCTAG-C CNTNAP1-related disorder Likely pathogenic (Sep 26, 2019)800937
17-42682839-C-T Inborn genetic diseases Uncertain significance (May 23, 2023)2525503
17-42682846-T-C Uncertain significance (Jul 29, 2022)1919335

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CCR10protein_codingprotein_codingENST00000332438 25029
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0005050.7011255930121256050.0000478
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.891302060.6300.00001112192
Missense in Polyphen4879.8690.60098949
Synonymous2.82691060.6510.00000580889
Loss of Function0.83868.660.6934.70e-779

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00006060.0000606
Ashkenazi Jewish0.0001140.0000994
East Asian0.00006450.0000544
Finnish0.000.00
European (Non-Finnish)0.00002030.0000176
Middle Eastern0.00006450.0000544
South Asian0.0001990.000196
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Receptor for chemokines SCYA27 and SCYA28. Subsequently transduces a signal by increasing the intracellular calcium ions level and stimulates chemotaxis in a pre-B cell line.;
Pathway
Chemokine signaling pathway - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);Intestinal immune network for IgA production - Homo sapiens (human);Peptide GPCRs;Chemokine signaling pathway;GPCRs, Class A Rhodopsin-like;Signaling by GPCR;Signal Transduction;Chemokine receptors bind chemokines;Peptide ligand-binding receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;G alpha (i) signalling events;GPCR downstream signalling (Consensus)

Recessive Scores

pRec
0.119

Intolerance Scores

loftool
0.481
rvis_EVS
0.3
rvis_percentile_EVS
72.01

Haploinsufficiency Scores

pHI
0.224
hipred
N
hipred_score
0.375
ghis
0.501

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.898

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Ccr10
Phenotype
muscle phenotype; cellular phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Gene ontology

Biological process
chemotaxis;immune response;G protein-coupled receptor signaling pathway;positive regulation of cytosolic calcium ion concentration;calcium-mediated signaling;cell chemotaxis;chemokine-mediated signaling pathway
Cellular component
endoplasmic reticulum;plasma membrane;integral component of plasma membrane;external side of plasma membrane;cell surface
Molecular function
G protein-coupled receptor activity;protein binding;C-C chemokine receptor activity;chemokine binding;C-C chemokine binding